Literature DB >> 8008210

Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system.

H De Vos1, G Bricca, J De Keyser, J P De Backer, P Bousquet, G Vauquelin.   

Abstract

Both [3H]clonidine and [3H]idazoxan bind to alpha 2 adrenoceptors. The former also labels imidazoline receptors, and the latter non-adrenergic idazoxan binding sites. In order to investigate whether the imidazoline receptors and non-adrenergic idazoxan binding sites are identical, we compared the binding characteristics of [3H]clonidine and [3H]idazoxan to these sites by radioligand binding experiments on ultra-thin slices and homogenates of human striatum. A good correlation was found between the effect of different ions on the binding characteristics of [3H]clonidine and [3H]idazoxan, and the affinities of most competing drugs. However, clonidine and rilmenidine displayed a 100- and 10-fold lower affinity, respectively, for the idazoxan binding sites than for the imidazoline receptors. Autoradiography with [3H]clonidine showed that high densities of imidazoline receptors were present in the striatum, pallidum, gyrus dentatus of the hippocampus, amygdala, and substantia nigra. Moderate densities were found throughout the cerebral cortex, thalamus and several brainstem nuclei including the nucleus olivarius inferior. Low densities were seen in the cerebellum, spinal cord and pituitary gland. As for the non-adrenergic sites labelled by [3H]idazoxan, the imidazoline receptors can be found in all major brain areas examined. However, there are some striking differences between the concentrations of imidazoline receptors and non-adrenergic idazoxan binding sites in certain brain regions. To reconcile distribution and pharmacologic data, we propose that imidazoline receptors and non-adrenergic idazoxan binding sites represent different proteins or protein complexes and that at least in the nucleus reticularis lateralis and the striatum, imidazoline receptors and non-adrenergic idazoxan binding sites may be physically associated. The regional distribution of alpha 2 adrenoceptors within the human CNS was determined by quantitative autoradiography with [3H]RX821002. The highest densities of alpha 2 adrenoceptors were found in the cerebral and cerebellar cortex, and certain regions in the medulla oblongata (floor of the IV ventricle, reticular formation, hypoglossal nucleus and nucleus olivarius inferior). No alpha 2 adrenoceptors were detected in the pituitary gland. There exists no relationship between the distribution pattern of imidazoline receptors and alpha 2 adrenoceptors, indicating that these binding sites are independent from each other.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8008210     DOI: 10.1016/0306-4522(94)90179-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  22 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 2.  Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?

Authors:  Andrew Holt
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

3.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

4.  The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.

Authors:  Svetlana Semenova; Athina Markou
Journal:  Eur Neuropsychopharmacol       Date:  2010-06-03       Impact factor: 4.600

5.  Imidazoleacetic acid-ribotide in vestibulo-sympathetic pathway neurons.

Authors:  Gay R Holstein; Victor L Friedrich; Giorgio P Martinelli
Journal:  Exp Brain Res       Date:  2016-07-13       Impact factor: 1.972

6.  The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin.

Authors:  J A Ruiz-Ortega; L Ugedo; J Pineda; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

7.  Contrasting effects of the imidazol(in)e alpha 2-adrenoceptor agonists, medetomidine, clonidine and UK 14,304 on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialysis and synaptosomal uptake studies.

Authors:  J W Dalley; S C Stanford
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Clonidine in paediatrics - a review.

Authors:  Sujatha Basker; Georgene Singh; Rebecca Jacob
Journal:  Indian J Anaesth       Date:  2009-06

9.  Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease.

Authors:  Claudia Rose; Fiona M Menzies; Maurizio Renna; Abraham Acevedo-Arozena; Silvia Corrochano; Oana Sadiq; Steve D Brown; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-02-27       Impact factor: 6.150

10.  The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type.

Authors:  J T Coull; B J Sahakian; J R Hodges
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.